Hanx Biopharmaceuticals (Wuhan) Launches Up to HK$586 Million Hong Kong IPO

MT Newswires Live12-15

Hanx Biopharmaceuticals (Wuhan) (HKG:3378) launched its initial public offering in Hong Kong on Monday, aiming to raise as much as HK$586.3 million.

The biopharmaceutical firm is offering 18.3 million H shares at an indicative price range of HK$28 to HK$32 apiece, according to a filing Monday.

The issuer expects to determine its final offer price on or before Dec. 19 and disclose the allocations on Dec. 22. It will start trading on the Hong Kong bourse on Dec. 23.

The company secured seven cornerstone investors who committed to subscribing to a total of HK$93.4 million worth of IPO shares.

Hanx Biopharmaceuticals will use the IPO proceeds for research and development of its core product HX009, as well as other key products including HX301 and HX044. Funds will also be used to advance the company's product pipeline and commercialize its portfolio.

ICBC International Securities, China Securities (International) Corporate Finance, China Merchants Securities (HK), Haitong International Securities, CCB International Capital, TFI Securities and Futures, ABCI Securities, SPDB International Capital, Livermore Holdings, Tiger Brokers (HK) Global, Shanxi Securities International, and Beta International Securities are the joint bookrunners of the IPO.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591369502?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591369502","market":"nz","top_or_hot":-1,"title":"Hanx Biopharmaceuticals (Wuhan) Launches Up to HK$586 Million Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> Hanx Biopharmaceuticals (Wuhan) (HKG:3378) launched its initial public offering in Hong Kong on Monday, aiming to raise as much as HK$586.3 million.</p><p>The biopharmaceutical firm is offering 18.3 million H shares at an indicative price range of HK$28 to HK$32 apiece, according to a filing Monday.</p><p>The issuer expects to determine its final offer price on or before Dec. 19 and disclose the allocations on Dec. 22. It will start trading on the Hong Kong bourse on Dec. 23.</p><p>The company secured seven cornerstone investors who committed to subscribing to a total of HK$93.4 million worth of IPO shares.</p><p>Hanx Biopharmaceuticals will use the IPO proceeds for research and development of its core product HX009, as well as other key products including HX301 and HX044. Funds will also be used to advance the company's product pipeline and commercialize its portfolio.</p><p>ICBC International Securities, <a href=\"https://laohu8.com/S/601066\">China Securities</a> (International) Corporate Finance, <a href=\"https://laohu8.com/S/CHMSF\">China Merchants Securities</a> (HK), Haitong International Securities, CCB International Capital, TFI Securities and Futures, ABCI Securities, SPDB International Capital, Livermore Holdings, Tiger Brokers (HK) Global, <a href=\"https://laohu8.com/S/002500\">Shanxi Securities</a> International, and Beta International Securities are the joint bookrunners of the IPO.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals (Wuhan) Launches Up to HK$586 Million Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals (Wuhan) Launches Up to HK$586 Million Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-15 09:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hanx Biopharmaceuticals (Wuhan) (HKG:3378) launched its initial public offering in Hong Kong on Monday, aiming to raise as much as HK$586.3 million.</p><p>The biopharmaceutical firm is offering 18.3 million H shares at an indicative price range of HK$28 to HK$32 apiece, according to a filing Monday.</p><p>The issuer expects to determine its final offer price on or before Dec. 19 and disclose the allocations on Dec. 22. It will start trading on the Hong Kong bourse on Dec. 23.</p><p>The company secured seven cornerstone investors who committed to subscribing to a total of HK$93.4 million worth of IPO shares.</p><p>Hanx Biopharmaceuticals will use the IPO proceeds for research and development of its core product HX009, as well as other key products including HX301 and HX044. Funds will also be used to advance the company's product pipeline and commercialize its portfolio.</p><p>ICBC International Securities, <a href=\"https://laohu8.com/S/601066\">China Securities</a> (International) Corporate Finance, <a href=\"https://laohu8.com/S/CHMSF\">China Merchants Securities</a> (HK), Haitong International Securities, CCB International Capital, TFI Securities and Futures, ABCI Securities, SPDB International Capital, Livermore Holdings, Tiger Brokers (HK) Global, <a href=\"https://laohu8.com/S/002500\">Shanxi Securities</a> International, and Beta International Securities are the joint bookrunners of the IPO.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1535","symbol_name":"港口运输股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2591369502","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591369502","pubTimestamp":1765763938,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hanx Biopharmaceuticals   launched its initial public offering in Hong Kong on Monday, aiming to raise as much as HK$586.3 million.The biopharmaceutical firm is offering 18.3 million H shares at an indicative price range of HK$28 to HK$32 apiece, according to a filing Monday.The issuer expects to determine its final offer price on or before Dec. 19 and disclose the allocations on Dec. 22. It will start trading on the Hong Kong bourse on Dec. 23.The company secured seven cornerstone investors who committed to subscribing to a total of HK$93.4 million worth of IPO shares.Hanx Biopharmaceuticals will use the IPO proceeds for research and development of its core product HX009, as well as other key products including HX301 and HX044. Funds will also be used to advance the company's product pipeline and commercialize its portfolio.ICBC International Securities, China Securities  Corporate Finance, China Merchants Securities , Haitong International Securities, CCB International Capital, TFI S","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1535":"港口运输股","BK1173":"海港与服务","03378":"翰思艾泰-B"},"translate_title":"汉克斯生物制药（武汉）最多5.86亿港元香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) (HKG:3378) launched its initial public offering in Hong Kong on Monday, aiming to raise as much as HK$586.3 million.The biopharmaceutical firm is offering 18.3 million H shares at an indicative price range of HK$28 to HK$32 apiece, according to a filing Monday.The issuer expects to determine its final offer price on or before Dec. 19 and disclose the allocations on Dec. 22. It will start trading on the Hong Kong bourse on Dec. 23.The company secured seven cornerstone investors who committed to subscribing to a total of HK$93.4 million worth of IPO shares.Hanx Biopharmaceuticals will use the IPO proceeds for research and development of its core product HX009, as well as other key products including HX301 and HX044. Funds will also be used to advance the company's product pipeline and commercialize its portfolio.ICBC International Securities, China Securities (International) Corporate Finance, China Merchants Securities (HK), Haitong International Securities, CCB International Capital, TFI Securities and Futures, ABCI Securities, SPDB International Capital, Livermore Holdings, Tiger Brokers (HK) Global, Shanxi Securities International, and Beta International Securities are the joint bookrunners of the IPO.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591369502","isCrawlerRequest":true}